Atea Pharmaceuticals Inc

AVIR

$4.04

Closing

▲1.00%

1D

▲32.46%

YTD

Market cap

$340.02M

52 week high

$5.19

52 week low

$2.77

Volume

223,048

Check if the stock is halal

Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.

Get started from just $3.99/month

Market cap

$340.02M

Analysts' Rating

HOLD

Price Target (Mean)

4

Total Analysts

4

P/E

Operating Margin

0.00%

Beta

0.16

Revenue Growth (Annual)

-100.00%

52 week high

$5.19

52 week low

$2.77

Div. Yield

%

EPS Annual Growth

17.65

Note on Purification and Zakat

  • Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly). 
  • If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
  • For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them. 

Company Profile

Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The Company is engaged in developing its product candidate, bemnifosbuvir, for the treatment of coronavirus disease 2019 (COVID-19), and its variants. The Company is also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV). The bemnifosbuvir (AT-527) for COVID-19 addresses key limitations of current therapies and explores combination therapy for specific patient populations. Bemnifosbuvir is an investigational, orally administered, non-mutagenic, non-teratogenic, direct-acting antiviral agent. The Company’s SUNRISE-3 is designed to evaluate bemnifosbuvir as monotherapy but also explores the effect of combination therapy in a smaller sub-set of patients who receive an antiviral drug along with bemnifosbuvir.